Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386735762> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4386735762 endingPage "jnumed.123.266141" @default.
- W4386735762 startingPage "jnumed.123.266141" @default.
- W4386735762 abstract "The prostate-specific membrane antigen (PSMA) inhibitor [177Lu]Lu-PSMA-617 has been previously demonstrated to be noninferior to docetaxel in achieving a biochemical response in chemotherapy-naïve metastatic castration-resistant prostate cancer patients. Here, we report the final analysis of overall survival (OS) for a phase 2 randomized, controlled trial. Methods: Forty chemotherapy-naïve, PSMA-positive metastatic castration-resistant prostate cancer patients were randomly assigned to [177Lu]Lu-PSMA-617 (n = 20) or docetaxel (n = 20). Thirty-five patients received treatment per the protocol. Survival analysis was done using Kaplan-Meier curves and the Cox regression model. Results: The mean follow-up duration was 33.4 mo. In intention-to-treat analysis, the median OS for the [177Lu]Lu-PSMA-617 and docetaxel arms was 15.0 mo (95% CI, 9.5-20.5 mo) and 15.0 mo (95% CI, 8.1-21.9 mo), respectively (P = 0.905). In per-protocol analysis, the median OS was 19.0 mo (95% CI, 12.3-25.7 mo) versus 15.0 mo (95% CI, 8.1-21.9 mo), respectively (P = 0.712). No significant difference in OS was observed between the 2 arms across the analyzed subgroups. Conclusion: Long-term outcomes with [177Lu]Lu-PSMA-617 administered earlier in the prechemotherapy setting are comparable to those with docetaxel." @default.
- W4386735762 created "2023-09-15" @default.
- W4386735762 creator A5009998252 @default.
- W4386735762 creator A5020081483 @default.
- W4386735762 creator A5021936759 @default.
- W4386735762 creator A5027749819 @default.
- W4386735762 creator A5038644822 @default.
- W4386735762 creator A5053724034 @default.
- W4386735762 creator A5058292173 @default.
- W4386735762 creator A5059547897 @default.
- W4386735762 date "2023-09-14" @default.
- W4386735762 modified "2023-09-26" @default.
- W4386735762 title "[<sup>177</sup>Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial" @default.
- W4386735762 cites W2511755939 @default.
- W4386735762 cites W2898661793 @default.
- W4386735762 cites W2984712394 @default.
- W4386735762 cites W3088199739 @default.
- W4386735762 cites W3130934287 @default.
- W4386735762 cites W3176208875 @default.
- W4386735762 cites W3217433724 @default.
- W4386735762 cites W4281979651 @default.
- W4386735762 cites W4296078278 @default.
- W4386735762 cites W4306776219 @default.
- W4386735762 cites W4315754639 @default.
- W4386735762 cites W4376134233 @default.
- W4386735762 doi "https://doi.org/10.2967/jnumed.123.266141" @default.
- W4386735762 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37709534" @default.
- W4386735762 hasPublicationYear "2023" @default.
- W4386735762 type Work @default.
- W4386735762 citedByCount "0" @default.
- W4386735762 crossrefType "journal-article" @default.
- W4386735762 hasAuthorship W4386735762A5009998252 @default.
- W4386735762 hasAuthorship W4386735762A5020081483 @default.
- W4386735762 hasAuthorship W4386735762A5021936759 @default.
- W4386735762 hasAuthorship W4386735762A5027749819 @default.
- W4386735762 hasAuthorship W4386735762A5038644822 @default.
- W4386735762 hasAuthorship W4386735762A5053724034 @default.
- W4386735762 hasAuthorship W4386735762A5058292173 @default.
- W4386735762 hasAuthorship W4386735762A5059547897 @default.
- W4386735762 hasConcept C10515644 @default.
- W4386735762 hasConcept C121608353 @default.
- W4386735762 hasConcept C126322002 @default.
- W4386735762 hasConcept C126894567 @default.
- W4386735762 hasConcept C143998085 @default.
- W4386735762 hasConcept C168563851 @default.
- W4386735762 hasConcept C20417620 @default.
- W4386735762 hasConcept C2776694085 @default.
- W4386735762 hasConcept C2780192828 @default.
- W4386735762 hasConcept C2781190966 @default.
- W4386735762 hasConcept C2989005 @default.
- W4386735762 hasConcept C3019894029 @default.
- W4386735762 hasConcept C71924100 @default.
- W4386735762 hasConceptScore W4386735762C10515644 @default.
- W4386735762 hasConceptScore W4386735762C121608353 @default.
- W4386735762 hasConceptScore W4386735762C126322002 @default.
- W4386735762 hasConceptScore W4386735762C126894567 @default.
- W4386735762 hasConceptScore W4386735762C143998085 @default.
- W4386735762 hasConceptScore W4386735762C168563851 @default.
- W4386735762 hasConceptScore W4386735762C20417620 @default.
- W4386735762 hasConceptScore W4386735762C2776694085 @default.
- W4386735762 hasConceptScore W4386735762C2780192828 @default.
- W4386735762 hasConceptScore W4386735762C2781190966 @default.
- W4386735762 hasConceptScore W4386735762C2989005 @default.
- W4386735762 hasConceptScore W4386735762C3019894029 @default.
- W4386735762 hasConceptScore W4386735762C71924100 @default.
- W4386735762 hasLocation W43867357621 @default.
- W4386735762 hasLocation W43867357622 @default.
- W4386735762 hasOpenAccess W4386735762 @default.
- W4386735762 hasPrimaryLocation W43867357621 @default.
- W4386735762 hasRelatedWork W1543388821 @default.
- W4386735762 hasRelatedWork W2010765098 @default.
- W4386735762 hasRelatedWork W2060708716 @default.
- W4386735762 hasRelatedWork W2094570582 @default.
- W4386735762 hasRelatedWork W2135620818 @default.
- W4386735762 hasRelatedWork W2407641156 @default.
- W4386735762 hasRelatedWork W2568045406 @default.
- W4386735762 hasRelatedWork W2588988563 @default.
- W4386735762 hasRelatedWork W2735900144 @default.
- W4386735762 hasRelatedWork W2770702948 @default.
- W4386735762 isParatext "false" @default.
- W4386735762 isRetracted "false" @default.
- W4386735762 workType "article" @default.